Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
LETTER
Elliot B Tapper, Jesus M Banales
No abstract text is available yet for this article.
July 26, 2021: Journal of Hepatology
#2
EDITORIAL
Peter R Galle, Ghassan Abou-Alfa
No abstract text is available yet for this article.
July 23, 2021: Journal of Hepatology
#3
LETTER
Marie Schultalbers, Denis Grote-Koska, Markus Cornberg, Julius J Schmidt, Benjamin Maasoumy
No abstract text is available yet for this article.
July 23, 2021: Journal of Hepatology
#4
LETTER
Pierre Deltenre, Astrid Marot
No abstract text is available yet for this article.
July 20, 2021: Journal of Hepatology
#5
LETTER
Sergio M Borgia, Stephen D Shafran
No abstract text is available yet for this article.
July 19, 2021: Journal of Hepatology
#6
LETTER
Junyu Long, Xinting Sang, Haitao Zhao
No abstract text is available yet for this article.
July 19, 2021: Journal of Hepatology
#7
LETTER
Florence Wong, Salvatore Piano, Paolo Angeli
No abstract text is available yet for this article.
July 17, 2021: Journal of Hepatology
#8
LETTER
Theresa Kirchner, Elmar Jaeckel, Christine S Falk, Britta Eiz-Vesper, Richard Taubert
No abstract text is available yet for this article.
July 17, 2021: Journal of Hepatology
#9
LETTER
Reply to 'Ceruloplasmin Variants Might Have Different Effects in Different Iron Overload Disorders'.
Elena Corradini, Luca Vittorio Valenti
No abstract text is available yet for this article.
July 15, 2021: Journal of Hepatology
#10
EDITORIAL
Antonio Saviano, Thomas F Baumert
No abstract text is available yet for this article.
July 15, 2021: Journal of Hepatology
#11
Claudia Montaldo, Michela Terri, Veronica Riccioni, Cecilia Battistelli, Veronica Bordoni, Gianpiero D'Offizi, Maria Giulia Prado, Flavia Trionfetti, Tiziana Vescovo, Eleonora Tartaglia, Raffaele Strippoli, Chiara Agrati, Marco Tripodi
BACKGROUND & AIMS: HCV SVR, achievable now by means of DAA therapy, identifies a new class of patients requiring medical surveillance to be designed in relation to the liver disease stage advancement. To this end, identification of both disease biomarkers and therapeutic targets appears necessary. METHODS: Extracellular Vesicles (EVs) purified from plasma of 15 healthy donors (HD), and 16 HCV infected patients before (T0) and after (T6) DAA treatment have been utilised for functional and miRNA cargo analysis...
July 13, 2021: Journal of Hepatology
#12
LETTER
Julian Pohl, Bernhard Gebauer, Pimrapat Gebert, Frank Tacke, Alexander Wree
No abstract text is available yet for this article.
July 12, 2021: Journal of Hepatology
#13
Pierre Brissot, Olivier Loréal
No abstract text is available yet for this article.
July 11, 2021: Journal of Hepatology
#14
Hannes Hagström, Tracey G Simon, Bjorn Roelstraete, Olof Stephansson, Jonas Söderling, Jonas F Ludvigsson
BACKGROUND AND AIMS: Maternal obesity has been linked to the development of cardiovascular disease and diabetes in offspring, but its relationship to non-alcoholic fatty liver disease (NAFLD) is unclear. METHODS: Through the nationwide ESPRESSO cohort study we identified all individuals in Sweden with biopsy-verified NAFLD ≤25 years of age diagnosed between 1992 and 2016 (n=165). These were matched on age, sex, and calendar year with up to 5 controls (n=717). Through linkage with the nationwide Swedish Medical Birth Register (MBR) we retrieved data on maternal early-pregnancy body mass index (BMI), and possible confounders, in order to calculate adjusted odds ratios (aORs) for future offspring NAFLD...
July 10, 2021: Journal of Hepatology
#15
Jordi Bruix, Stephen L Chan, Peter R Galle, Lorenza Rimassa, Bruno Sangro
The last five years have witnessed relevant advances in the systemic therapy of hepatocellular carcinoma. New data have emerged since the development of the EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma in 2018. Drugs licensed in some countries now include four oral multi-tyrosine kinase inhibitors (sorafenib, lenvatinib, regorafenib and cabozantinib), one antiangiogenic antibody (ramucirumab) and four immune checkpoint inhibitors, alone or in combination (atezolizumab in combination with bevacizumab, ipilimumab in combination with nivolumab, nivolumab and pembrolizumab in monotherapy)...
July 10, 2021: Journal of Hepatology
#16
LETTER
Francesca Lodato, Anna Larocca, Antonietta D'Errico, Vincenzo Cennamo
No abstract text is available yet for this article.
July 10, 2021: Journal of Hepatology
#17
EDITORIAL
Javier Vaquero, Verena Keitel
No abstract text is available yet for this article.
July 9, 2021: Journal of Hepatology
#18
LETTER
Takako Inoue, Shintaro Yagi, Yasuhito Tanaka
No abstract text is available yet for this article.
July 8, 2021: Journal of Hepatology
#19
LETTER
Nipun Verma, Rohit Mehtani, Ajay Duseja
No abstract text is available yet for this article.
July 8, 2021: Journal of Hepatology
#20
LETTER
Masaru Enomoto, Takeji Umemura, Fumitaka Suzuki
No abstract text is available yet for this article.
July 7, 2021: Journal of Hepatology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
